This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

First in Man Study With SLV341

This study has been terminated.
(The study was terminated on June 25th, 2009 due to strategic decision)
Quintiles, Inc.
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: January 30, 2009
Last updated: April 27, 2010
Last verified: April 2010
First in man study with single and multiple rising doses with SLV341

Condition Intervention Phase
Diabetes Drug: SLV341 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:
  • Safety and tolerability parameters: adverse event, vital signs, 12-Lead ECG, continuous lead II ECG monitoring, laboratory safety variables and physical examination. [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters: Plasma: Cmax, tmax, AUC, t½, λz, CL/F, and Vz/F. Urine: Aeurine, fe, and CLR [ Time Frame: 1 - 28 days ]
  • Pharmacodynamic parameters: biochemistry and 24 h Holter monitoring. [ Time Frame: 28 days ]
  • Interaction with Midazolam [ Time Frame: 24 hours ]

Enrollment: 87
Study Start Date: July 2008
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: SLV341
5 - 1000mg once daily
Placebo Comparator: B Drug: placebo


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Inclusion Criteria healthy Exclusion Criteria not healthy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00887445

United Kingdom
S341.1.001 Site #
London, United Kingdom
Sponsors and Collaborators
Solvay Pharmaceuticals
Quintiles, Inc.
Study Director: Ingrid Meuwsen Solvay Pharmaceuticals
  More Information Identifier: NCT00887445     History of Changes
Other Study ID Numbers: S341.1.001
Study First Received: January 30, 2009
Last Updated: April 27, 2010

Keywords provided by Solvay Pharmaceuticals:
First in Man
diabetes processed this record on August 23, 2017